MIRA
INFORM REPORT
|
Report Date : |
20.02.2013 |
IDENTIFICATION DETAILS
|
Name : |
GUANGZHOU BAIRUI MEDICINE
CO., LTD. |
|
|
|
|
Registered Office : |
Unit 12ab, Xinyu Building, No. 81, Nonglinxia Road, Yuexiu District,
Guangzhou, Guangdong Province 510080 Pr |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
19.02.2001 |
|
|
|
|
Com. Reg. No.: |
440104000119967 |
|
|
|
|
Legal Form : |
Limited Liabilities Co. |
|
|
|
|
Line of Business : |
Subject is engaged in selling pharmaceutical raw materials and
preparation. |
|
|
|
|
No. of Employees : |
7 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
Slow but Correct |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
china - ECONOMIC OVERVIEW
Since the late 1970s China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role - in 2010 China became the world's largest exporter. Reforms began with the phasing out of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, creation of a diversified banking system, development of stock markets, rapid growth of the private sector, and opening to foreign trade and investment. China has implemented reforms in a gradualist fashion. In recent years, China has renewed its support for state-owned enterprises in sectors it considers important to "economic security," explicitly looking to foster globally competitive national champions. After keeping its currency tightly linked to the US dollar for years, in July 2005 China revalued its currency by 2.1% against the US dollar and moved to an exchange rate system that references a basket of currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi against the US dollar was more than 20%, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual appreciation. The restructuring of the economy and resulting efficiency gains have contributed to a more than tenfold increase in GDP since 1978. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2010 stood as the second-largest economy in the world after the US, having surpassed Japan in 2001. The dollar values of China's agricultural and industrial output each exceed those of the US; China is second to the US in the value of services it produces. Still, per capita income is below the world average. The Chinese government faces numerous economic challenges, including: (a) reducing its high domestic savings rate and correspondingly low domestic demand; (b) sustaining adequate job growth for tens of millions of migrants and new entrants to the work force; (c) reducing corruption and other economic crimes; and (d) containing environmental damage and social strife related to the economy's rapid transformation. Economic development has progressed further in coastal provinces than in the interior, and by 2011 more than 250 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of population control policy is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and economic development. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on nuclear and alternative energy development. In 2010-11, China faced high inflation resulting largely from its credit-fueled stimulus program. Some tightening measures appear to have controlled inflation, but GDP growth consequently slowed to near 9% for 2011. An economic slowdown in Europe is expected to further drag Chinese growth in 2012. Debt overhang from the stimulus program, particularly among local governments, and a property price bubble challenge policy makers currently. The government's 12th Five-Year Plan, adopted in March 2011, emphasizes continued economic reforms and the need to increase domestic consumption in order to make the economy less dependent on exports in the future. However, China has made only marginal progress toward these rebalancing goals.
|
Source : CIA |
company name and address
GUANGZHOU BAIRUI MEDICINE CO., LTD.
UNIT 12AB, XINYU BUILDING, NO. 81, NONGLINXIA
ROAD, YUEXIU DISTRICT, GUANGZHOU, GUANGDONG PROVINCE 510080 PR CHINA
TEL: 86 (0) 20-87658479 FAX: 86 (0) 20-87659730
EXECUTIVE SUMMARY
INCORPORATION DATE : fEB. 19, 2001
REGISTRATION NO. : 440104000119967
REGISTERED LEGAL FORM : LIMITED LIABILITIES CO.
CHIEF EXECUTIVE :
MR. CHENG HAO (CHAIRMAN)
STAFF STRENGTH :
7
REGISTERED CAPITAL : CNY 1,800,000
BUSINESS LINE :
TRADING
TURNOVER :
CNY 13,110,000 (UNAUDITED, AS OF
DEC. 31, 2012)
EQUITIES :
CNY 530,000 (UNAUDITED, AS OF DEC. 31, 2012)
PAYMENT :
AVERAGE
MARKET CONDITION : AVERAGE
FINANCIAL CONDITION :
FAIRLY STABLE
OPERATIONAL TREND : FAIR
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY 6.24= USD 1
Adopted
abbreviations:
ANS - amount not stated NS
- not stated SC - subject company (the
company inquired by you)
NA - not available CNY
- China Yuan Renminbi
Note: SC’s correct name should be the heading one.
SC was registered as a Limited liabilities co. at local Administration
for Industry & Commerce (AIC - The official body of issuing and renewing
business license) on Feb. 19, 2001.
Company Status: Limited liabilities co. This form of business in PR
China is defined as a legal person. No more than fifty shareholders contribute its registered
capital jointly. Shareholders bear limited liability to the extent of
shareholding, and the co. is liable for its debts only to extent of its
total assets. The characteristics of this form of co. are as follows: Upon the establishment of the
co., an investment certificate is issued to the each of shareholders. The board of directors is
comprised of three to thirteen members. The minimum registered capital
for a co. is CNY 30,000. Shareholders may take their
capital contributions in cash or by means of tangible assets or intangible
assets such as industrial property and non-patented technology. Cash contributed by all
shareholders must account for at least 30% of the registered capital. Existing shareholders have
pre-exemption right to purchase shares of the co. offered for sale by the
other shareholders and to subscribe for the newly increased registered
capital of the co.
SC’s registered business scope includes wholesaling proprietary Chinese
medicines, chemical raw materials, chemical medicine preparations, antibiotics
API, antibiotics, biochemical drugs preparation, textile machinery equipment,
construction engineering equipment, chemical raw materials; importing and
exporting commodities.
SC is mainly engaged in selling pharmaceutical raw materials and
preparation.
Mr. Cheng Hao is legal representative and chairman of SC at present.
SC is known to have approx. 7 employees at present.
SC is currently operating at the above stated address, and this address
houses its operating office in the commercial zone of Guangzhou. The detailed
premise information is unspecified.
http://www.gzbr.com.cn/
The design is professional and the content is well organized. At present the
web site is in Chinese and English versions.
E-mail: iris@gzbr.com.cn
Changes of its
registered information are as follows:
|
Date of change |
Item |
Before the change |
After the change |
|
Unknown |
Registered no. |
4401042016709 |
Present one |
MAIN SHAREHOLDERS:
Name % of Shareholding
Cheng Hao 84
Gu Kaifeng 16
Legal
representative and Chairman:
Mr. Cheng Hao is currently
responsible for the overall management of SC.
Working Experience(s):
At present Working
in SC as legal representative and chairman.
Supervisor:
-----------------------
Gu Kaifeng
Note: The given contact person Iris Zeng is working in SC at present.
SC is mainly engaged in selling pharmaceutical raw materials and
preparation.
SC’s products mainly include API, formulations, intermediates, etc.
SC sources its materials 70% from domestic market and 30% from overseas
market. SC sells 80% of its products in domestic market and 20% to overseas
market.
The buying terms of SC include Check, T/T, L/C and Credit of 30-60 days.
The payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.
Note: SC declined
to release its major suppliers and clients.
According to SC’s website:
Anhui Bairui Bioengineering Co., Ltd.
Overall payment appraisal:
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment
experience (through current enquiry with SC's suppliers), our delinquent payment
and our debt collection record concerning SC.
Trade payment experience: SC did not provide any name of
trade/service suppliers and we have no other sources to conduct the enquiry at
present.
Delinquent payment record: None
in our database.
Debt collection record: No overdue amount
owed by SC was placed to us for collection within the last 6 years.
SC’s accountant refused to release the bank details.
Balance Sheet
Unit: CNY’000
|
|
As
of Dec. 31, 2012 |
|
Cash & bank |
50 |
|
Inventory |
10,270 |
|
Accounts receivable |
5,120 |
|
Other receivables |
3,430 |
|
Other current assets |
670 |
|
|
------------------ |
|
Current assets |
19,540 |
|
Fixed assets net value |
10 |
|
Long term investment |
880 |
|
Projects under construction |
0 |
|
Intangible and other assets |
0 |
|
|
------------------ |
|
Total assets |
20,430 |
|
|
=========== |
|
Short loan |
0 |
|
Accounts payable |
19,030 |
|
Advances from clients |
0 |
|
Other Accounts payable |
690 |
|
Other current liabilities |
180 |
|
|
------------------ |
|
Current liabilities |
19,900 |
|
Long term liabilities |
0 |
|
|
------------------ |
|
Total liabilities |
19,900 |
|
Equities |
530 |
|
|
------------------ |
|
Total liabilities & equities |
20,430 |
|
|
=========== |
Income Statement
Unit: CNY’000
|
|
As of Dec. 31,
2012 |
|
Turnover |
13,110 |
|
Cost of goods sold |
10,410 |
|
Sales expense |
870 |
|
Management expense |
1,790 |
|
Finance expense |
0 |
|
Profit before tax |
10 |
|
Less: profit tax |
0 |
|
Profits |
10 |
Note: The above financial for Yr2012 are not audited.
Important Ratios
=============
|
|
As
of Dec. 31, 2012 |
|
*Current ratio |
0.98 |
|
*Quick ratio |
0.47 |
|
*Liabilities to assets |
0.97 |
|
*Net profit margin (%) |
0.08 |
|
*Return on total assets (%) |
0.05 |
|
*Inventory /Turnover ×365 |
286 days |
|
*Accounts receivable/Turnover ×365 |
143 days |
|
*Turnover/Total assets |
0.64 |
|
* Cost of goods sold/Turnover |
0.79 |
PROFITABILITY:
AVERAGE
The turnover of SC appears average.
SC’s net profit margin is average.
SC’s return on total assets is average.
SC’s cost of goods sold is average, comparing with its turnover.
LIQUIDITY: FAIR
The current ratio of SC is maintained in a fair level.
SC’s quick ratio is maintained in a fair level.
The inventory of SC appears large.
The accounts receivable of SC appears fairly large.
SC has no short-term loan in 2012.
SC’s turnover is in a fair level, comparing with the size of its total
assets.
LEVERAGE: FAIR
The debt ratio of SC is high.
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Fairly stable.
SC is considered small-sized in its line with fairly stable financial
conditions. The large amount of inventory and accounts receivable could be a
threat to SC’s financial condition.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.29 |
|
|
1 |
Rs.84.09 |
|
Euro |
1 |
Rs.72.44 |
INFORMATION DETAILS
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
MIRA
INFORM REPORT
|
Report Date : |
20.02.2013 |
|
|
|
|
Tel No.: |
86 20 87658479 |
|
Fax No.: |
86 20 87659730 |
IDENTIFICATION DETAILS
|
Name : |
GUANGZHOU BAIRUI MEDICINE
CO., LTD. |
|
|
|
|
Registered Office : |
Unit 12ab, Xinyu Building, No. 81, Nonglinxia Road, Yuexiu District,
Guangzhou, Guangdong Province 510080 Pr |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
19.02.2001 |
|
|
|
|
Com. Reg. No.: |
440104000119967 |
|
|
|
|
Legal Form : |
Limited Liabilities Co. |
|
|
|
|
Line of Business : |
Subject is engaged in selling pharmaceutical raw materials and
preparation. |
|
|
|
|
No. of Employees : |
7 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
Slow but Correct |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
china - ECONOMIC OVERVIEW
Since the late 1970s China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role - in 2010 China became the world's largest exporter. Reforms began with the phasing out of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, creation of a diversified banking system, development of stock markets, rapid growth of the private sector, and opening to foreign trade and investment. China has implemented reforms in a gradualist fashion. In recent years, China has renewed its support for state-owned enterprises in sectors it considers important to "economic security," explicitly looking to foster globally competitive national champions. After keeping its currency tightly linked to the US dollar for years, in July 2005 China revalued its currency by 2.1% against the US dollar and moved to an exchange rate system that references a basket of currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi against the US dollar was more than 20%, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual appreciation. The restructuring of the economy and resulting efficiency gains have contributed to a more than tenfold increase in GDP since 1978. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2010 stood as the second-largest economy in the world after the US, having surpassed Japan in 2001. The dollar values of China's agricultural and industrial output each exceed those of the US; China is second to the US in the value of services it produces. Still, per capita income is below the world average. The Chinese government faces numerous economic challenges, including: (a) reducing its high domestic savings rate and correspondingly low domestic demand; (b) sustaining adequate job growth for tens of millions of migrants and new entrants to the work force; (c) reducing corruption and other economic crimes; and (d) containing environmental damage and social strife related to the economy's rapid transformation. Economic development has progressed further in coastal provinces than in the interior, and by 2011 more than 250 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of population control policy is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and economic development. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on nuclear and alternative energy development. In 2010-11, China faced high inflation resulting largely from its credit-fueled stimulus program. Some tightening measures appear to have controlled inflation, but GDP growth consequently slowed to near 9% for 2011. An economic slowdown in Europe is expected to further drag Chinese growth in 2012. Debt overhang from the stimulus program, particularly among local governments, and a property price bubble challenge policy makers currently. The government's 12th Five-Year Plan, adopted in March 2011, emphasizes continued economic reforms and the need to increase domestic consumption in order to make the economy less dependent on exports in the future. However, China has made only marginal progress toward these rebalancing goals.
|
Source : CIA |
company name and address
GUANGZHOU BAIRUI MEDICINE CO., LTD.
UNIT 12AB, XINYU BUILDING, NO. 81, NONGLINXIA
ROAD, YUEXIU DISTRICT, GUANGZHOU, GUANGDONG PROVINCE 510080 PR CHINA
TEL: 86 (0) 20-87658479 FAX: 86 (0) 20-87659730
EXECUTIVE SUMMARY
INCORPORATION DATE : fEB. 19, 2001
REGISTRATION NO. : 440104000119967
REGISTERED LEGAL FORM : LIMITED LIABILITIES CO.
CHIEF EXECUTIVE :
MR. CHENG HAO (CHAIRMAN)
STAFF STRENGTH :
7
REGISTERED CAPITAL : CNY 1,800,000
BUSINESS LINE :
TRADING
TURNOVER :
CNY 13,110,000 (UNAUDITED, AS OF
DEC. 31, 2012)
EQUITIES :
CNY 530,000 (UNAUDITED, AS OF DEC. 31, 2012)
PAYMENT :
AVERAGE
MARKET CONDITION : AVERAGE
FINANCIAL CONDITION :
FAIRLY STABLE
OPERATIONAL TREND : FAIR
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY 6.24= USD 1
Adopted
abbreviations:
ANS - amount not stated NS
- not stated SC - subject company (the
company inquired by you)
NA - not available CNY
- China Yuan Renminbi
Note: SC’s correct name should be the heading one.
SC was registered as a Limited liabilities co. at local Administration for
Industry & Commerce (AIC - The official body of issuing and renewing
business license) on Feb. 19, 2001.
Company Status: Limited liabilities co. This form of business in PR
China is defined as a legal person. No more than fifty shareholders contribute its registered
capital jointly. Shareholders bear limited liability to the extent of
shareholding, and the co. is liable for its debts only to extent of its
total assets. The characteristics of this form of co. are as follows: Upon the establishment of the
co., an investment certificate is issued to the each of shareholders. The board of directors is
comprised of three to thirteen members. The minimum registered capital
for a co. is CNY 30,000. Shareholders may take their
capital contributions in cash or by means of tangible assets or intangible
assets such as industrial property and non-patented technology. Cash contributed by all
shareholders must account for at least 30% of the registered capital. Existing shareholders have
pre-exemption right to purchase shares of the co. offered for sale by the
other shareholders and to subscribe for the newly increased registered
capital of the co.
SC’s registered business scope includes wholesaling proprietary Chinese medicines,
chemical raw materials, chemical medicine preparations, antibiotics API,
antibiotics, biochemical drugs preparation, textile machinery equipment,
construction engineering equipment, chemical raw materials; importing and
exporting commodities.
SC is mainly engaged in selling pharmaceutical raw materials and
preparation.
Mr. Cheng Hao is legal representative and chairman of SC at present.
SC is known to have approx. 7 employees at present.
SC is currently operating at the above stated address, and this address
houses its operating office in the commercial zone of Guangzhou. The detailed
premise information is unspecified.
http://www.gzbr.com.cn/
The design is professional and the content is well organized. At present the
web site is in Chinese and English versions.
E-mail: iris@gzbr.com.cn
Changes of its
registered information are as follows:
|
Date of change |
Item |
Before the change |
After the change |
|
Unknown |
Registered no. |
4401042016709 |
Present one |
MAIN SHAREHOLDERS:
Name
% of Shareholding
Cheng Hao 84
Gu Kaifeng 16
Legal
representative and Chairman:
Mr. Cheng Hao is currently
responsible for the overall management of SC.
Working Experience(s):
At present Working
in SC as legal representative and chairman.
Supervisor:
-----------------------
Gu Kaifeng
Note: The given contact person Iris Zeng is working in SC at present.
SC is mainly engaged in selling pharmaceutical raw materials and
preparation.
SC’s products mainly include API, formulations, intermediates, etc.
SC sources its materials 70% from domestic market and 30% from overseas
market. SC sells 80% of its products in domestic market and 20% to overseas
market.
The buying terms of SC include Check, T/T, L/C and Credit of 30-60 days.
The payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.
Note: SC declined
to release its major suppliers and clients.
According to SC’s website:
Anhui Bairui Bioengineering Co., Ltd.
Overall payment appraisal:
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment
experience (through current enquiry with SC's suppliers), our delinquent
payment and our debt collection record concerning SC.
Trade payment experience: SC did not provide any name of
trade/service suppliers and we have no other sources to conduct the enquiry at
present.
Delinquent payment record: None
in our database.
Debt collection record: No overdue amount
owed by SC was placed to us for collection within the last 6 years.
SC’s accountant refused to release the bank details.
Balance Sheet
Unit: CNY’000
|
|
As
of Dec. 31, 2012 |
|
Cash & bank |
50 |
|
Inventory |
10,270 |
|
Accounts receivable |
5,120 |
|
Other receivables |
3,430 |
|
Other current assets |
670 |
|
|
------------------ |
|
Current assets |
19,540 |
|
Fixed assets net value |
10 |
|
Long term investment |
880 |
|
Projects under construction |
0 |
|
Intangible and other assets |
0 |
|
|
------------------ |
|
Total assets |
20,430 |
|
|
=========== |
|
Short loan |
0 |
|
Accounts payable |
19,030 |
|
Advances from clients |
0 |
|
Other Accounts payable |
690 |
|
Other current liabilities |
180 |
|
|
------------------ |
|
Current liabilities |
19,900 |
|
Long term liabilities |
0 |
|
|
------------------ |
|
Total liabilities |
19,900 |
|
Equities |
530 |
|
|
------------------ |
|
Total liabilities & equities |
20,430 |
|
|
=========== |
Income Statement
Unit: CNY’000
|
|
As of Dec. 31,
2012 |
|
Turnover |
13,110 |
|
Cost of goods sold |
10,410 |
|
Sales expense |
870 |
|
Management expense |
1,790 |
|
Finance expense |
0 |
|
Profit before tax |
10 |
|
Less: profit tax |
0 |
|
Profits |
10 |
Note: The above financial records for Yr2012 are not audited.
Important Ratios
=============
|
|
As
of Dec. 31, 2012 |
|
*Current ratio |
0.98 |
|
*Quick ratio |
0.47 |
|
*Liabilities to assets |
0.97 |
|
*Net profit margin (%) |
0.08 |
|
*Return on total assets (%) |
0.05 |
|
*Inventory /Turnover ×365 |
286 days |
|
*Accounts receivable/Turnover ×365 |
143 days |
|
*Turnover/Total assets |
0.64 |
|
* Cost of goods sold/Turnover |
0.79 |
PROFITABILITY:
AVERAGE
The turnover of SC appears average.
SC’s net profit margin is average.
SC’s return on total assets is average.
SC’s cost of goods sold is average, comparing with its turnover.
LIQUIDITY: FAIR
The current ratio of SC is maintained in a fair level.
SC’s quick ratio is maintained in a fair level.
The inventory of SC appears large.
The accounts receivable of SC appears fairly large.
SC has no short-term loan in 2012.
SC’s turnover is in a fair level, comparing with the size of its total
assets.
LEVERAGE: FAIR
The debt ratio of SC is high.
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Fairly stable.
SC is considered small-sized in its line with fairly stable financial
conditions. The large amount of inventory and accounts receivable could be a
threat to SC’s financial condition.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.29 |
|
|
1 |
Rs.84.09 |
|
Euro |
1 |
Rs.72.44 |
INFORMATION DETAILS
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)